logo
Scientists just designed the perfect cacio e pepe recipe

Scientists just designed the perfect cacio e pepe recipe

Fast Company06-05-2025
Chances are, if you're not an Italian grandma or a skilled home chef from Rome, you've probably messed up while trying to make cacio e pepe. At least, that's the thesis underpinning the scientific study ' Phase behavior of Cacio e Pepe sauce,' published on April 29 in the journal Physics of Fluids.
The study—conducted by a group of scientists from the University of Barcelona, the Max Planck Institute for the Physics of Complex Systems in Germany, the University of Padova in Italy, and the Institute of Science and Technology Austria—is pretty much what its title suggests: a full-on scientific investigation into the most 'optimized recipe' for the creamy, peppery pasta dish.
'We're Italians living abroad, and we often get together for dinner to enjoy traditional recipes from home,' says Ivan Di Terlizzi, the study's lead author and a postdoctoral researcher at the Max Planck Institute. 'Among the dishes we've cooked, cacio e pepe came up several times, and every time, we were struck by how hard it is to get the sauce right. That's when we realized it might actually be an interesting physical system to study. And of course, there was also the very practical motivation of avoiding the heartbreak of wasting good pecorino!'
A very brief history of pasta-based physics experiments
This isn't the first time that pasta has been used as inspiration for physicists. Probably the most famous example of 'pasta as experiment,' Di Terlizzi says, is the observation that spaghetti almost never breaks cleanly in half, tending to snap into three or more fragments instead. This fact originally puzzled renowned physicist Richard Feynman (who died in 1988) and wasn't fully explained until 2005, when a team of French physicists showed that it's caused by cascading cracks traveling along the pasta.
Another example, Di Terlizzi adds, is the physics of ring-shaped polymers, which are 'notoriously hard to understand.' A study in 2014 used a type of circular pasta, which the researchers called 'anelloni,' to explain why these looped polymers behave so strangely in experiments. With cacio e pepe, the physics question of interest has to do with the sauce's unusual behavior under heat.
'The main goal of our work wasn't just culinary; it was to explore the physics of this system,' Di Terlizzi says. 'The sauce's behavior under heat shares features with many physical and biological phenomena, like phase transitions or the formation of membrane-less organelles inside cells. The recipe is, in a sense, the practical byproduct of everything we learned.'
The most optimal cacio e pepe recipe, according to scientists
Cacio e pepe traditionally only includes three ingredients: pasta, pecorino Romano cheese, and black pepper. While it seems like a simple enough concoction, the sauce's creamy smoothness (the backbone of the dish) can be quite finicky to achieve. When the temperature gets too high or the mixing of cheese and pasta water isn't done carefully, the cheese proteins will denature—essentially 'unfolding' and losing their normal 3D structure.
In the unfolded state, the proteins then stick together and the emulsion breaks. 'Instead of a creamy consistency, you get a gooey mess, which we call salsa impazzita. . . that is, crazy sauce,' Di Terlizzi says. The physics-based solution to 'crazy sauce'? It's all about starch.
It turns out that, by perfecting the ratio of starch in the pasta water to cheese mass, the cacio e pepe sauce becomes far more resistant to heat, which stabilizes the emulsion and prevents clumping.
'Without starch, the so-called 'mozzarella phase' kicks in at around 65°C, where the proteins start forming large aggregates,' Di Terlizzi says. 'But if the starch concentration is above 1% relative to the cheese mass, the clumps stay small, and temperature becomes much less critical, making it much easier to get a good result.' This is similar to using polymers to stabilize emulsions in soft matter physics, he adds.
'Phase behavior of cacio e pepe sauce' contains ultra-detailed steps to a foolproof cacio e pepe, but here are the instructions in condensed terms:
Step 1: For a pasta dish for 'two hungry people,' start with 300 grams of the preferred tonnarelli pasta—or opt for spaghetti or rigatoni, if you must. From there, you'll need 200 grams of cheese. 'Traditionalists would insist on using only pecorino Romano DOP [protected designation of origin], but some argue that up to 30% parmigiano Reggiano DOP is acceptable; though this remains a point of debate,' the recipe notes. Proceed based on your own personally held cheese preferences.
Step 2: To prepare the sauce, dissolve 5 grams of starch—like potato or corn starch—in 50 grams of water. Heat this mixture gently until it thickens and turns from cloudy to nearly clear. This is your starch gel.
Step 3: Add 100 grams of water to the starch gel. Instead of manually grating the cheese into the resulting liquid, blend the two together to achieve a homogeneous sauce. Finish the sauce by adding black pepper to taste (for best results, toast the pepper in a pan before adding).
Step 4: To prepare the pasta, cook in slightly salted water until it is al dente. Save some of the pasta cooking water before draining. Once the pasta has been drained, let it cool down for up to a minute to prevent the excessive heat from destabilizing the sauce. Finally, mix the pasta with the sauce, ensuring even coating, and adjust the consistency by gradually adding reserved pasta water as needed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nature's warning sign of democracy's fragility
Nature's warning sign of democracy's fragility

Boston Globe

time9 hours ago

  • Boston Globe

Nature's warning sign of democracy's fragility

Advertisement Leafless and forlorn, it stands there like a reminder of the fragility of everything that surrounds us: A small green beetle comes and lays its eggs in the bark, a few seasons pass, and what seemed invulnerable, the very definition of life and strength, now awaits the chain saw. The author's three ash trees. Amanda S. Merullo I did some research and read about a new treatment that could save some of the trees — or at least prolong their lives — if administered before too much damage has been done. Yesterday a young arborist from a local company came for an inspection and gave us the good news that our three ash trees might be saved by the injection of a special pesticide, noxious only to the EAB. I love those trees — they have a special meaning for me, as if they're emblems of the history we've made in this place — and so, without any hesitation, we signed up for the program. Advertisement My wife, Amanda, and I spent two months in southern Italy last winter, way down in the heel of the boot. The land there is so different from where we live in Western Massachusetts, flat as a tabletop and a stranger to snow and ice. There are said to be 60 million olive trees in that part of Italy — some of them, according to locals, more than 500 years old. But 20 years ago some of those gorgeous trees started to become infected with the bacterium Xylella fastidiosa , carried by insects with cute names like spittlebug and meadow froghopper. So far, 20 million olive trees have died. When you ride the train south from the beautiful city of Lecce, all you see out the window is a landscape of devastation, row after row of dead olive trees, thousands of them, their thick, beautifully twisted old trunks holding up nothing but a canopy of withered gray branches. The price of Italian olive oil more My late mother, who had a philosophical side, liked to compare trees to the human body. Some of them thrive and live long lives, she said, and some of them die young. Some are healthy and some diseased, but eventually they all go back into the soil, food for new life. Advertisement Lately, I've been thinking of trees more in terms of whole societies, of nations, of democracies. Healthy for a long stretch of time, seemingly invulnerable, they're attacked by an invasive beetle or bacterium that feeds on them from the inside. The damage is invisible at first, but it doesn't take long for the leaves to wither, the trunks to weaken, the once-vibrant branches to morph into skeletal arms. Next week the experts are coming to inject our three beautiful ash trees with a substance that's supposed to prove fatal to most or all of the emerald borers. I hope we didn't wait too long to begin the treatment.

Israeli quantum startup Qedma just raised $26 million, with IBM joining in
Israeli quantum startup Qedma just raised $26 million, with IBM joining in

Yahoo

time5 days ago

  • Yahoo

Israeli quantum startup Qedma just raised $26 million, with IBM joining in

Despite their imposing presence, quantum computers are delicate beasts, and their errors are among the main bottlenecks that the quantum computing community is actively working to address. Failing this, promising applications in finance, drug discovery, and materials science may never become real. That's the reason why Google touted the error correction capacities of its latest quantum computing chip, Willow. And IBM is both working on delivering its own 'fault-tolerant' quantum computer by 2029 and collaborating with partners like Qedma, an Israeli startup in which it also invested, as TechCrunch learned exclusively. While most efforts focus on hardware, Qedma specializes in error mitigation software. Its main piece of software, QESEM, or quantum error suppression and error mitigation, analyzes noise patterns to suppress some classes of errors while the algorithm is running and mitigate others in post-processing. Qedma's co-founder and chief scientific officer, Professor Dorit Aharonov, once described as a member of 'quantum royalty' for her and her father's contributions to the field, said this enables quantum circuits up to 1,000 times larger to run accurately on today's hardware, without waiting for further advancements on error correction at the computer level. IBM itself does both quantum hardware and software, and some of its partners, like French startup Pasqal, also develop their own hardware. But it sees value as well in partnering with companies more narrowly focusing on the software layer, like Qedma and Tiger Global-backed Finnish startup Algorithmiq, its VP of Quantum, Jay Gambetta, told TechCrunch. That's because IBM thinks driving quantum further requires a community effort. 'If we all work together, I do think it's possible that we will get scientific accepted definitions of quantum advantage in the near future, and I hope that we can then turn them into more applied use cases that will grow the industry,' Gambetta said. 'Quantum advantage' usually refers to demonstrating the usefulness of quantum over classical computers. 'But useful is a very subjective term,' Gambetta said. In all likelihood, it will first apply to an academic problem, not a practical one. In this context, it may take more than one attempt to build consensus that it's not just another artificial or overly constrained scenario. Still, having a quantum computer execute a program that a classical computer can't simulate with the same accuracy would be an important step for the industry — and Qedma claims it is getting closer. 'It's possible that already within this year, we'll be able to demonstrate with confidence that the quantum advantage is here,' CEO and co-founder Asif Sinay said. With a doctorate in physics, Sinay previously worked as a physicist at Magic Leap, then a multi-billion-worth AR company with a large R&D center in Israel. Like the founders of several Israeli startups, from Metacafe to Wiz, he is also a Talpion — an alum from Israel's elite military program Talpiot, where one of his classmates was Lior Litwak. Litwak is now a managing partner at Israeli VC firm Glilot Capital Partners, which led Qedma's $26 million Series A through its early growth fund, Glilot+, which he heads. The round included participation from existing investors such as TPY Capital, which backed Qedma's $4.7 million seed round in 2020, as well as new investors including Korean Investment Partners — and IBM. Since last September, Qedma has been available through IBM's Qiskit Functions Catalog, which makes quantum more accessible to end users. Sinay noted the synergies between the two companies, but emphasized that Qedma's plans are hardware-agnostic. The startup has already conducted a demo on the Aria computer from IonQ, a publicly listed U.S. company focused on trapped ion quantum computing. In addition, Qedma has an evaluation agreement with an unnamed partner Sinay described as 'the largest company in the market.' Recently, it also presented its collaboration with Japan's RIKEN on how to combine quantum with supercomputers. The joint Q2B Tokyo presentation was co-delivered by Qedma's CTO and third co-founder, Professor Netanel Lindner. An associate professor of theoretical physics and research group lead at Technion, he told TechCrunch he is hoping that some of his former doctorate students — or others they know — will join Qedma as part of the startup's hiring efforts. According to Sinay, Qedma will use the proceeds from its latest funding round to grow its team from around 40 to between 50 and 60 people. Some of these new recruits will be researchers and software engineers, but he said the startup also plans to hire for marketing and sales roles. 'We are selling our software to the end users, and our partners are the hardware manufacturers.' For hardware manufacturers like IBM, this software layer addresses the fact that a quant at a bank or a chemist who could leverage quantum are not experts in how to run circuits in the presence of noise. However, they know their respective domains and the conditions they want to set. 'So you want to be able to write the problem and say, I want it to run with this accuracy, I'm OK with this much usage of a quantum computer, and this much usage of a classical computer,' Gambetta said. 'They want [these] to be essentially little options that they can put into their software; and that's exactly what Qedma is doing, as well as some of [the] other partners we're working with.' Some researchers are already taking advantage of this via Qiskit Functions, or through partnerships that research institutions have established with Qedma and its industry peers. But the debate is still open as to when these experiments will become larger, and when quantum advantage will materialize for the broader world. Qedma hopes to accelerate the timeline by providing a shortcut. Unlike error correction at the computer level, which adds overhead that limits scalability, Qedma's approach doesn't require more quantum bits, or qubits. 'Our claim is that we can get quantum advantage even before a million qubits are achieved,' Lindner said. However, other companies are approaching that issue from different angles. For instance, French startup Alice & Bob raised $104 million earlier this year to develop a fault-tolerant quantum computer whose architecture relies on 'cat qubits,' which are inherently protected against certain errors, reducing the need for more qubits. But Qedma is not dismissive of the race for more qubits; since it acts as a booster either way, its team wants hardware to have as many qubits as possible, and the best qubits possible. In practice, though, it will be hard to maximize both at once, just like software-based error mitigation typically means longer runtimes. The best choice will depend on the specific task — but first, quantum will have to get to those tasks.

Influencers of COVID Vaccine Response in Dialysis Patients
Influencers of COVID Vaccine Response in Dialysis Patients

Medscape

time5 days ago

  • Medscape

Influencers of COVID Vaccine Response in Dialysis Patients

TOPLINE: Among patients undergoing maintenance dialysis, chronic heart failure and hypoalbuminaemia were significantly associated with a poor humoral response at 3 months after completing three doses of the SARS-CoV-2 messenger RNA (mRNA) vaccine; however, no association was observed between haemodialysis-related variables and antibody response levels. METHODOLOGY: Researchers in France performed a retrospective observational study to identify factors associated with a poor humoral response after completion of the SARS-CoV-2 mRNA vaccination schedule (three doses) in 80 adult patients (median age, 71 years; 44% women) undergoing maintenance dialysis for more than 3 months. Anti-SARS-CoV-2 antibody levels were measured using a quantitative serology test at two timepoints: 3 months after the third dose and either 7 months after the third dose or 3 months after the fourth (second booster) dose. On the basis of antibody titres at 3 months after the third dose, the patients were classified as low responders (n = 28; anti-SARS-CoV-2 antibody level, 50-1830 AU/mL) and responders (n = 52; anti-SARS-CoV-2 antibody level > 1830 AU/mL). Data on laboratory values, dialysis parameters, history of kidney disease, chronic heart failure, and immunosuppressive treatments were extracted from medical records. The primary endpoint was the humoral immune response, evaluated using the SARS-CoV-2 antibody level at 3 months after the third dose. TAKEAWAY: Low responders were more likely to have chronic heart failure (P < .00001), worse functional abilities and well-being (P = .004), hypoalbuminaemia (P < .001), lymphopenia (P = .003), rhesus status positivity (P = .02), and no response to a hepatitis B virus vaccine (P = .02) than responders. No significant differences were observed between both groups regarding the history of kidney transplantation, use of immunosuppressive therapy, and haemodialysis parameters. In multivariate analysis, chronic heart failure (odds ratio [OR], 20.63; P < .0001) and lower serum albumin levels (OR, 0.63; P = .0004) were associated with a poor response to the SARS-CoV-2 mRNA vaccine. However, post-vaccination SARS-CoV-2 infection rates did not differ significantly between low responders and responders (P = .59). IN PRACTICE: "CHF [chronic heart failure], like CKD [chronic kidney disease], is also an immunocompromised condition, which could explain the reduced vaccine response," the authors wrote. "The French government currently recommends administering a SARS-CoV-2 vac­cine booster every six months for immunocompromised patients," they added. SOURCE: This study was led by Pierre Laurent, Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France. It was published online on June 23, 2025, in BMC Nephrology. LIMITATIONS: The retrospective, single-centre design of the study introduced potential biases. The small patient population limited the statistical power for group comparisons and restricted the number of variables that could be included in the analysis. Moreover, the study included only patients who received SARS-CoV-2 mRNA vaccines, excluding those who initially received viral-vector-based vaccines. DISCLOSURES: This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store